BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui

BioPharma DiveLilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

Endpoints NewsXTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise

Lonza NewsHigh-throughput chromatography in bioprocess analytics - News-Medical

FierceBiotechIndivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2

FierceBiotechBMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific

Endpoints NewsWhat we heard at a health tech conference in Boston

Promega BlogThe Filter You Didn’t Choose

FierceBiotechLabcorp raises full-year guidance, boosted by diagnostics, lab services

FierceBiotechLeo Pharma pays $50M for Replay and its preclinical skin disease gene therapy

Endpoints NewsCVS' healthcare delivery chief eyes potential in clinical AI

PharmaVoicePfizer deals extend patent life for a top-selling rare disease drug

FierceBiotechBeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui